Biopharmaceutics. Группа авторов

lipolysis products. Pharmaceutical Research 26 (2): 361.

      16 [16] Kleberg, K., Jacobsen, F., Fatouros, D.G., and Müllertz, A. (2010). Biorelevant media simulating fed state intestinal fluids: colloid phase characterization and impact on solubilization capacity. Journal of Pharmaceutical Sciences 99 (8): 3522–3532.

      17 [17] Streng, W.H., Hsi, S.K., Helms, P.E., and Tan, H.G.H. (1984). General treatment of pH‐solubility profiles of weak acids and bases and the effects of different acids on the solubility of a weak base. Journal of Pharmaceutical Sciences 73 (12): 1679–1684.

      18 [18] Newman, A. (2017). Rational design for amorphous solid dispersions. In: Developing Solid Oral Dosage Forms, 2e (eds. Y. Qiu, Y. Chen, G.G.Z. Zhang, et al.), 497–518. Boston: Academic Press.

      19 [19] van der Vossen, A.C., van der Velde, I., Smeets, O.S.N.M. et al. (2017). Formulating a poorly water soluble drug into an oral solution suitable for paediatric patients; lorazepam as a model drug. European Journal of Pharmaceutical Sciences 100: 205–210.

      20 [20] Saokham, P., Muankaew, C., Jansook, P., and Loftsson, T. (2018). Solubility of cyclodextrins and drug/cyclodextrin complexes. Molecules (Basel, Switzerland) 23 (5): 1161. https://doi.org/10.3390/molecules23051161. PMID: 29751694; PMCID: PMC6099580.